Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | SMYD2 | Q9NRG4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5745020 | 1.00 | CYP3A4 (0.34) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL5830430 | 1.00 | CYP3A4 (0.34) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL5831033 | 0.78 | MAPT (0.40) | — | |
| SCHEMBL5747649 | 0.78 | MAPT (0.40) | — | |
| SCHEMBL3777347 | 0.78 | MAPT (0.40) | — | |
| SCHEMBL3991039 | 0.77 | LMNA (0.34) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL3778543 | 0.75 | MAPT (0.35) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL13014511 | 0.75 | MAPT (0.35) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL21379414 | 0.75 | CYP3A4 (0.33) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL21379413 | 0.75 | CYP3A4 (0.33) | CYP3A4HTTSMN1; SMN2SMYD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115740-B2 | Pyrimido compounds having antiproliferative activity | HOFFMANN-LA ROCHE INC. (US) | 2006-10-03 | — | — | US | disclosed |
| EP-1615928-A1 | PYRIMIDO COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004089955-A1 | PYRIMIDO COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2004-10-21 | — | — | WO | disclosed |
| US-20040204427-A1 | Pyrimido compounds having antiproliferative activity | CHEN YI (US) | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204427-A1 | Pyrimido compounds having antiproliferative activity | FGFR3, FGFR1, FGFR4 | CYP3A4 1954/4885HTT 3570/4885SMN1; SMN2 2014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.